DDrare: Database of Drug Development for Rare Diseases

58. 肥大型心筋症
［臨床試験数：92，薬物数：126（DrugBank：35），標的遺伝子数：40，標的パスウェイ数：141］

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE; 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride; Acetylcysteine; Adenosine; Air; Alcohol; Antiarrhythmic drugs; Atorvastatin; BNP; BNP blood sample test; Behavioral: Lifestyle; Bluefish; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one; CK-3773274; CK-3773274 (10 - 30 mg); CK-3773274 (5 - 15 mg); CK-3773274 - Granules in Capsule; CK-3773274 - Tablets; CT-G20; Candesartan; Carnitine; Cufence; Cyclosporine; Cyclosporine A; Device: Insertable cardiac monitor; Device: Magnetic resonance imaging (MRI) with gadolinium enhancement; Device: Magnetic resonance imaging (MRI) without gadolinium enhancement; Device: Use of bioanalytical assay to monitor plasma levels of perhexiline; Diagnostic Test: Air venous plethysmography; Diagnostic Test: Echocardiography; Diagnostic Test: Electrocardiogram; Diagnostic Test: Exercise Stress Transthoracic Echocardiogram; Diagnostic Test: Holter ECG; Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy; Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD; Diltiazem; Diovan; Diovan 160 mg; Diovan 40 mg; Diovan 80 mg; Dobutamine; Echo and myocardial contrast echocardiography perfusion imaging; Eleclazine; Endothelial function biomarkers; Entresto; GS-6615 3 mg; GS-6615 3 mg Pink; GS-6615 3 mg White; GS-6615 6 mg; GS-6615 6 mg White; Gadolinium; Gradient; Gutron 2,5mg; Gutron 5mg; Hyperpolarized 13C-Pyruvate; LCZ696; LCZ696 100 mg; LCZ696 200 mg; LCZ696 50 mg; Losartan; Losartan Bluefish 50 mg; MAVACAMTEN; MEK162; MIDODRINE HYDROCHLORIDE; MONITOR; MYK-461; Mangafodipir; Mavacamten; Metoprolol; Metoprolol Succinate; Midodrine; N-acetylcysteine; Nitrate; Other: Exercise echocardiography; Other: Mangafodipir trisodium; Other: Walk distance test; Perhexiline; Perxexiline; Pexsig; Phosphorous; Piperazine; Pirfenidone; Procedure: 3D electrocardiographic mapping (ECM); Procedure: B-lines SE; Procedure: Coronary flow reserve SE; Procedure: Diastolic function SE; Procedure: Echocardiography (TEE); Procedure: Left ventricular contractile reserve SE; Procedure: Left ventricular outflow tract gradient SE; Procedure: Mitral regurgitation SE; Procedure: Pulmonary hemodynamics SE; Procedure: RF catheter ablation; Procedure: trans-right ventricular alcohol septal ablation (TRVASA); Pyrazole; RANEXA; RANEXA*60CPR 500MG R.P.; RANEXA*60CPR 750MG R.P.; RANOLAZINE; Ranexa; Ranolazine; Ranolazine 1000 mg PR tablets; Ranolazine 500 mg PR tablets; Ranolazine 750 mg PR tablets; Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; Regadenoson; SACUBITRIL VALSARTAN; Sacubitril; Sacubitril/Valsartan; Sacubitril/valsartan; Sodium Nitrate; Sodium nitrate; Spironolactone; Treatment BX1514M; Trientine; Trientine Dihydrochloride; Trientine dihydrochloride; Triethylinetetramine dihydrochloride; Trimetazidine; Trimetazidine Dihydrochloride 20mg; Trimetazidine dihydrochloride; VALSARTAN; Valsartan; Vastarel; Vastarel 20mg film coated tablets; [MYK-461]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03953989 (ClinicalTrials.gov)	October 2016	13/5/2019	Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy	A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy	HCM - Hypertrophic Non-Obstructive Cardiomyopathy	Drug: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die	IRCCS San Raffaele	Menarini International Operations Luxembourg SA	Completed	18 Years	80 Years	All	26	Phase 2	Italy
2	NCT01721967 (ClinicalTrials.gov)	November 2012	2/11/2012	Ranolazine for the Treatment of Chest Pain in HCM Patients	Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation	Hypertrophic Cardiomyopathy	Drug: Ranolazine	Duke University	Gilead Sciences	Completed	18 Years	N/A	All	14	Phase 4	United States
3	EUCTR2011-004507-20-DE (EUCTR)	02/07/2012	17/10/2011	SHCM	RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY) - RESTYLE- HCM STUDY	symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 17.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets INN or Proposed INN: RANOLAZINE	Menarini International Operations Luxembourg S.A.	NULL	Not Recruiting			Female: yes Male: yes	100		Spain;Germany;Italy
4	EUCTR2011-004507-20-IT (EUCTR)	22/02/2012	08/03/2012	SHMC	RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS	symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	Spain;Germany;Italy
5	EUCTR2011-004507-20-ES (EUCTR)	19/01/2012	13/10/2011	SHMC	RANOLAZINE IN PATIENTS WITH SYMPTOMATICHYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDYASSESSING THE EFFECTS ON EXERCISE CAPACITY,DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS	symptomatic hypertrophic cardiomyopathy (SHCM) MedDRA version: 14.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]	Trade Name: Ranexa Product Code: Ranolazine 500 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 750 mg PR tablets INN or Proposed INN: RANOLAZINE Trade Name: Ranexa Product Name: Ranolazine 1000 mg PR tablets INN or Proposed INN: RANOLAZINE	Menarini International Operations Luxembourg S.A.	NULL	Not Recruiting			Female: yes Male: yes	100		Spain;Germany;Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03953989
(ClinicalTrials.gov)

October 2016

13/5/2019

Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy

HCM - Hypertrophic Non-Obstructive Cardiomyopathy

Drug: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die

IRCCS San Raffaele

Menarini International Operations Luxembourg SA

Completed

18 Years

80 Years

All

Phase 2

Italy

NCT01721967
(ClinicalTrials.gov)

November 2012

2/11/2012

Ranolazine for the Treatment of Chest Pain in HCM Patients

Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation

Hypertrophic Cardiomyopathy

Drug: Ranolazine

Duke University

Gilead Sciences

Completed

18 Years

N/A

All

Phase 4

United States

EUCTR2011-004507-20-DE
(EUCTR)

02/07/2012

17/10/2011

SHCM

RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS (RESTYLE- HCM STUDY) - RESTYLE- HCM STUDY

symptomatic hypertrophic cardiomyopathy (SHCM)
MedDRA version: 17.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Trade Name: Ranexa
Product Code: Ranolazine 500 mg PR tablets
INN or Proposed INN: RANOLAZINE
Trade Name: Ranexa
Product Name: Ranolazine 750 mg PR tablets
INN or Proposed INN: RANOLAZINE
Trade Name: Ranexa
Product Name: Ranolazine 1000 mg PR tablets
INN or Proposed INN: RANOLAZINE

Menarini International Operations Luxembourg S.A.

NULL

Not Recruiting

Female: yes
Male: yes

100

Spain;Germany;Italy

EUCTR2011-004507-20-IT
(EUCTR)

22/02/2012

08/03/2012

SHMC

RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS

symptomatic hypertrophic cardiomyopathy (SHCM)
MedDRA version: 14.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.

NULL

Not Recruiting

Female: yes
Male: yes

100

Phase 2

Spain;Germany;Italy

EUCTR2011-004507-20-ES
(EUCTR)

19/01/2012

13/10/2011

SHMC

RANOLAZINE IN PATIENTS WITH SYMPTOMATICHYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDYASSESSING THE EFFECTS ON EXERCISE CAPACITY,DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS

symptomatic hypertrophic cardiomyopathy (SHCM)
MedDRA version: 14.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

Menarini International Operations Luxembourg S.A.

NULL

Not Recruiting

Female: yes
Male: yes

100

Spain;Germany;Italy